BONE BIOLOGICS CORPORATION: financing cash flow
Financing cash flow for BONE BIOLOGICS CORPORATION. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BONE BIOLOGICS CORPORATION financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-11-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 4,700,341 | USD | 2026-03-02 | 10-K · 0001493152-26-008564 |
| 2024-01-01 | 2024-12-31 | 4,423,497 | USD | 2026-03-02 | 10-K · 0001493152-26-008564 |
| 2023-01-01 | 2023-12-31 | 5,044,161 | USD | 2025-02-26 | 10-K · 0001493152-25-008383 |
| 2022-01-01 | 2022-12-31 | 4,429,860 | USD | 2024-02-21 | 10-K · 0001493152-24-007432 |
| 2021-01-01 | 2021-12-31 | 7,903,951 | USD | 2023-03-30 | 10-K · 0001493152-23-009799 |
| 2020-01-01 | 2020-12-31 | 402,788 | USD | 2022-03-15 | 10-K · 0001493152-22-006850 |
| 2019-01-01 | 2019-12-31 | 2,320,000 | USD | 2021-04-15 | 10-K · 0001493152-21-008887 |
| 2018-01-01 | 2018-12-31 | 4,369,979 | USD | 2020-03-30 | 10-K · 0001493152-20-004977 |
| 2017-01-01 | 2017-12-31 | 3,400,000 | USD | 2019-03-29 | 10-K · 0001493152-19-004221 |
| 2016-01-01 | 2016-12-31 | 6,833,111 | USD | 2018-04-02 | 10-K · 0001493152-18-004423 |
| 2015-01-01 | 2015-12-31 | 2,000,000 | USD | 2017-03-30 | 10-K · 0001493152-17-002998 |
| 2014-01-01 | 2014-12-31 | 5,390,000 | USD | 2016-03-28 | 10-K · 0001493152-16-008297 |
| 2013-01-01 | 2013-12-31 | 524,533 | USD | 2015-03-31 | 10-K · 0001493152-15-001120 |
| 2012-11-01 | 2013-10-31 | 5,996 | USD | 2014-02-13 | 10-K · 0001493152-14-000445 |
| 2011-11-01 | 2012-10-31 | 6,557 | USD | 2014-02-13 | 10-K · 0001493152-14-000445 |
| 2010-11-01 | 2011-10-31 | 3,597 | USD | 2013-01-29 | 10-K · 0001493152-13-000132 |
| 2009-11-01 | 2010-10-31 | 5,681 | USD | 2012-01-30 | 10-K · 0001387131-12-000151 |
Related financial histories
- BONE BIOLOGICS CORPORATION: total assets
- BONE BIOLOGICS CORPORATION: total liabilities
- BONE BIOLOGICS CORPORATION: stockholders equity
- BONE BIOLOGICS CORPORATION: cash and cash equivalents
- BONE BIOLOGICS CORPORATION: net income or loss
- BONE BIOLOGICS CORPORATION: operating cash flow
- BONE BIOLOGICS CORPORATION: retained earnings or deficit
- BONE BIOLOGICS CORPORATION: basic weighted-average shares
- BONE BIOLOGICS CORPORATION: diluted weighted-average shares
- BONE BIOLOGICS CORPORATION: basic earnings per share
- BONE BIOLOGICS CORPORATION: diluted earnings per share
- BONE BIOLOGICS CORPORATION: income tax expense or benefit
- BONE BIOLOGICS CORPORATION: net property, plant and equipment
- BONE BIOLOGICS CORPORATION: share-based compensation expense
- BONE BIOLOGICS CORPORATION: operating income or loss
- BONE BIOLOGICS CORPORATION: current assets
- BONE BIOLOGICS CORPORATION: interest expense
- BONE BIOLOGICS CORPORATION: current liabilities
- BONE BIOLOGICS CORPORATION: current accounts payable
- BONE BIOLOGICS CORPORATION: operating expenses
- BONE BIOLOGICS CORPORATION: research and development expense
Inspect the source
- Entity
- BONE BIOLOGICS CORPORATION / CIK 0001419554
- Captured
- 2026-09-20T08:02:52.100Z
- SEC response SHA-256
7c2684db7febb4ea6b03577e138dc91ed20e12534f1d96c178894d4b68a7b815
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001419554.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))